Apixaban (Eliquis)

Trade Name : ELIQUIS

E.R. Squibb & Sons, L.L.C.

TABLET, FILM COATED

Strength 2.5 mg/1

Storage and handling for ELIQUIS

APIXABAN Factor Xa Inhibitor [EPC],Factor Xa Inhibitors [MoA]

Disclaimer

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Apixaban (Eliquis) which is also known as ELIQUIS and Manufactured by E.R. Squibb & Sons, L.L.C.. It is available in strength of 2.5 mg/1 per ml. Read more

Apixaban (Eliquis) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • Warnings and Precautions, Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a011/2019
  • (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS
  • Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant .
  • (B) SPINAL/EPIDURAL HEMATOMA
  • Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
  • Arrayn- [see ]
  • Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary .
  • Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated .
  • WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA
  • See full prescribing information for complete boxed warning.
  • (B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. n
  • ELIQUIS is a factor Xa inhibitor indicated:
  • (1.3n- 1.4n- 1.5)
  • No data
  • Arrayn- Array
  • Arrayn- Array
  • Arrayn- Array
  • Arrayn- Array
  • No data
  • u2022
  • (3)
  • ELIQUIS is contraindicated in patients with the following conditions:
  • No data
  • The following clinically significant adverse reactions are discussed in greater detail in other sections of the prescribing information.
  • Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
  • Most common adverse reactions (>1%) are related to bleeding. n
  • Arrayn- www.fda.gov/medwatch
  • Apixaban is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to apixaban and increase the risk of bleeding. Inducers of CYP3A4 and P-gp decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events.
  • (2.5n- 7.1n- 12.3)
  • (7.2n- 12.3)
  • No data
  • Pregnancy:
  • Lactation:
  • Severe Hepatic Impairment:
  • Overdose of ELIQUIS increases the risk of bleeding .
  • In controlled clinical trials, orally administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25u00a0mg twice daily for 7 days or 50 mg once daily for 3 days) had no clinically relevant adverse effects.
  • In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20-mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively. Thus, administration of activated charcoal may be useful in the management of ELIQUIS overdose or accidental ingestion. An agent to reverse the anti-factor Xa activity of apixaban is available.
  • ELIQUIS (apixaban), a factor Xa (FXa) inhibitor, is chemically described as 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1-pyrazolo[3,4-]pyridine-3-carboxamide. Its molecular formula is CHNO, which corresponds to a molecular weight of 459.5. Apixaban has the following structural formula:
  • Apixaban is a white to pale-yellow powder. At physiological pH (1.2-6.8), apixaban does not ionize; its aqueous solubility across the physiological pH range is ~0.04 mg/mL.
  • ELIQUIS tablets are available for oral administration in strengths of 2.5 mg and 5 mg of apixaban with the following inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide (2.5 mg tablets) or red iron oxide (5 mg tablets).
  • No data
  • Carcinogenesis:
  • Mutagenesis:
  • in vitro
  • in vivo/in vitro
  • in vivo
  • Impairment of Fertility:
  • Apixaban administered to female rats at doses up to 1000 mg/kg/day from implantation through the end of lactation produced no adverse findings in male offspring (F1 generation) at doses up to 1000 mg/kg/day, a dose resulting in exposure to unbound apixaban that is 5 times the human exposure. Adverse effects in the F1-generation female offspring were limited to decreased mating and fertility indices at u2265200 mg/kg/day (a dose resulting in exposure to unbound apixaban that is u22655 times the human exposure).
  • No data
  • No data
  • Advise patients to read the FDA-approved patient labeling (Medication Guide).
  • Advise patients of the following:
  • Marketed by:Bristol-Myers Squibb CompanyPrinceton, New Jersey 08543 USAandPfizer IncNew York, New York 10017 USA
  • [PRINT CODES]
  • ELIQUISn n- (apixaban)n- tablets
  • What is the most important information I should know about ELIQUIS?
  • What is ELIQUIS?
  • ELIQUIS is a prescription medicine used to:
  • It is not known if ELIQUIS is safe and effective in children.
  • Who should not take ELIQUIS?
  • Do not take ELIQUIS if you:
  • What should I tell my doctor before taking ELIQUIS?
  • Before you take ELIQUIS, tell your doctor if you:
  • Tell all of your doctors and dentists that you are taking ELIQUIS. They should talk to the doctor who prescribed ELIQUIS for you, before you have surgery, medical or dental procedure.
  • Tell your doctor about all the medicines you take, includingn- What is the most important information I should know about ELIQUIS?
  • Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
  • How should I take ELIQUIS?
  • What are the possible side effects of ELIQUIS?
  • Tell your doctor if you have any side effect that bothers you or that does not go away.
  • These are not all of the possible side effects of ELIQUIS. For more information, ask your doctor or pharmacist.
  • Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
  • How should I store ELIQUIS?
  • Store ELIQUIS at room temperature between 68u00b0F to 77u00b0F (20u00b0C to 25u00b0C).
  • Keep ELIQUIS and all medicines out of the reach of children.
  • General Information about ELIQUIS
  • Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ELIQUIS for a condition for which it was not prescribed. Do not give ELIQUIS to other people, even if they have the same symptoms that you have. It may harm them.
  • If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about ELIQUIS that is written for health professionals.
  • For more information, call 1-855-354-7847 (1-855-ELIQUIS) or go to www.ELIQUIS.com.
  • What are the ingredients in ELIQUIS?
  • Active ingredient: apixaban.
  • Inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide (2.5 mg tablets) or red iron oxide (5 mg tablets).
  • This Medication Guide has been approved by the U.S. Food and Drug Administration.n n n
  • Marketed by:Bristol-Myers Squibb CompanyPrinceton, New Jersey 08543 USAandPfizer IncNew York, New York 10017 USA
  • All other trademarks are property of their respective companies.
  • See section for a complete list of available packages of ELIQUIS.
  • 60 TabletsNDC 0003-0893-21ELIQUISn (apixaban) tablets2.5 mgDISPENSE WITH MEDICATION GUIDERx onlyBristol-Myers SquibbPfizer
  • 60 TabletsNDC 0003-0894-21ELIQUISn (apixaban) tablets5 mgDISPENSE WITH MEDICATION GUIDERx onlyBristol-Myers SquibbPfizer
  • ELIQUISn (apixaban) tabletsNDC 0003-3764-7430-Day Starter PackRx onlyn
  • 30-Day Starter Pack5 mg per tabletfor the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)DISPENSE WITH MEDICATION GUIDEPlease see the enclosed full Prescribing Information, including Boxed Warnings and Medication Guide
  • Contains Two Wallets74 tablets, 5 mg per tablet
  • Wallet 1: Days 1-14Start with Wallet 1
  • Wallet 2: Days 15-30Switch to Wallet 2 on Day 15
  • Bristol-Myers SquibbPfizer

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Dossiers and Stability Studies

Dossiers and Stability Studies

STABILITY STUDIES STABILITY, BA / BE STUDIES Due to our active

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64036 Products

GNH India brings over 10 years of experience in Comparator Sourcing services from India and RoW markets.

US NDC

71253 Products

GNH India brings over 10 years of experience in Comparator Sourcing services from India and RoW markets.

Canadian DIN

51047 Products

GNH India brings over 10 years of experience in Comparator Sourcing services from India and RoW markets.

Swiss Drugs

150 Products

GNH India brings over 10 years of experience in Comparator Sourcing services from India and RoW markets.

NZ Drugs

13298 Products

GNH India brings over 10 years of experience in Comparator Sourcing services from India and RoW markets.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2023 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.